← Back to screener

SUTRO BIOPHARMA, INC. STRO

Rank #2161 · Nasdaq · $0.2B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
31.2
P/E
-0.7
P/B
1.01
ROE
-152.0%
Op. Margin
-384.3%
Debt Ratio
229%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -0.7x, P/B 1.01x. Ranks in the top 55% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -152.0%. Ranks in the top 95% of the universe.

Safety ★★☆☆☆
Weak

Debt ratio 229%. Ranks in the top 66% of the universe. Above 200% signals meaningful leverage risk.

Growth ★☆☆☆☆
Poor

Revenue decline of 8.5% year over year. Ranks in the top 81% of the universe.

Valuation is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2018$0.1B$0.0B$0.0B$-0.1B2.3-50
2019$0.1B$-0.0B$-0.0B$-0.1B-37.2-101
2020$0.0B$-0.0B$-0.0B$-0.1B-96.9-54
2021$0.0B$-0.1B$-0.1B$0.1B-129.847
2022$0.0B$-0.1B$-0.1B$0.1B-166.391
2023$0.1B$-0.1B$-0.1B$0.3B-159.257
2024$0.1B$-0.1B$-0.1B$0.3B-190.3127
2025$0.1B$-0.2B$-0.2B$0.1B-384.3229

← See the full screener